Conatus Pharmaceuticals Inc. (CNAT)
(Delayed Data from NSDQ)
$0.90 USD
+0.05 (5.88%)
Updated May 3, 2019 03:59 PM ET
After-Market: $0.90 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Histogen Inc. [CNAT]
Reports for Purchase
Showing records 101 - 120 ( 226 total )
Company: Histogen Inc.
Industry: Medical - Products
Company: Histogen Inc.
Industry: Medical - Products
Company: Histogen Inc.
Industry: Medical - Products
3Q17 Recap: Waiting for Pipeline Development Announcement by YE; Model Tweaks, PT to $17
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Histogen Inc.
Industry: Medical - Products
Company: Histogen Inc.
Industry: Medical - Products
Company: Histogen Inc.
Industry: Medical - Products
Company: Histogen Inc.
Industry: Medical - Products
Company: Histogen Inc.
Industry: Medical - Products
Company: Histogen Inc.
Industry: Medical - Products
Company: Histogen Inc.
Industry: Medical - Products
Good Sign for a Pipeline Beyond Emricasan; IDN-7314 Granted Orphan Drug Designation for PSC; Affirm Buy IDN-
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Histogen Inc.
Industry: Medical - Products
Company: Histogen Inc.
Industry: Medical - Products
We are dropping coverage of CNAT shares to reallocate our research resources.
Provider: Roth Capital Partners, Inc.
Company: Histogen Inc.
Industry: Medical - Products
Coverage Update - Healthcare
Provider: Roth Capital Partners, Inc.
Company: Histogen Inc.
Industry: Medical - Products
Corrected - Coverage Update - Healthcare
Provider: Roth Capital Partners, Inc.
Company: Histogen Inc.
Industry: Medical - Products
Company: Histogen Inc.
Industry: Medical - Products
Company: Histogen Inc.
Industry: Medical - Products
1Q Recap: Novartis Opts in With ENCORE-LF Initiation; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Histogen Inc.
Industry: Medical - Products
Company: Histogen Inc.
Industry: Medical - Products
Company: Histogen Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.